Showing 1081-1090 of 23044 results for "".
The Essential Role of Death Certificates in Public Health
https://reachmd.com/programs/advances-in-long-term-care-medicine/the-essential-role-of-death-certificates-in-public-health/4071/Death certificates are essential to the creation of public health policies and determination of funding allocation. In addition, death certificates can bring public health epidemics to the forefront. Dr. Jeffrey Levine, clinical associate professor of medicine at New York Medical College, discussesCommitment to Clinical Evidence in Regenerative Aesthetics
https://practicaldermatology.com/series/c-suite-chats/commitment-to-clinical-evidence-in-regenerative-aesthetics/54693/Laura Ellis, MD, CEO and Co-Founder of LevEllis, Inc., discusses the current state of aesthetic regenerative medicine and the importance of clinical evidence as the field continues to advance.Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
https://reachmd.com/programs/clinicians-roundtable/advances-attr-cm-diagnostics-therapeutics/49055/In the past decade, significant strides have been made in diagnosing and treating patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Increased disease awareness, non-invasive diagnostic tools like scintigraphy, and AI-assisted screening have led to earlier detection and improved outcomes.Managing Refractory Chronic Cough: Strategies for Accurate Diagnosis and Effective Care
https://reachmd.com/programs/deep-breaths-updates-chest/managing-refractory-chronic-cough-strategies-for-accurate-diagnosis-and-effective-care/32866/Refractory chronic cough can persist for years despite guideline-based therapy, significantly affecting patients’ physical, social, and psychological wellbeing. Leading experts Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss explain how to distinguish RCC from other types of chronic cough, ouPediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
https://reachmd.com/programs/project-oncology/pediatric-sickle-cell-disease-analyzing-trends-in-medication-utilization/36515/Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribinCan Medical Leadership Be Taught?
https://reachmd.com/programs/inspired-to-act/can-medical-leadership-be-taught/5476/Are great medical leaders made or born? Can great leadership be developed? What is it about certain personalities that brings people to collaborate while other personalities foster dissension? Joining host Dr. Martin Samuels to discuss these topics is the former dean of both the Harvard Medical schoNew products and trends in contraception
https://reachmd.com/programs/clinicians-roundtable/new-products-and-trends-in-contraception/1610/The female condom. The Five year Progestin IUD. The Patch. The ring. These are just some of the contraceptives introduced in the past five years. What does the future hold? With us today is Doctor Robert Hatcher, a professor of Gynecology and Obstetrics at the Emory University School of MeCase in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC
https://reachmd.com/programs/cme/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Cases From the Real World: 91-Year-Old Patient With Wet AMD and a Submacular Hemorrhage
https://reachmd.com/programs/cme/Cases-From-the-Real-World-91-Year-Old-Patient-With-Wet-AMD-and-a-Submacular-Hemorrhage/33168/Hear how Drs. Danny Mammo and Ted Leng are using second-generation retinal agents to manage patients with PEDs from nAMD.Cases From the Real World: 61-Year-Old With Wet AMD With a High Treatment Burden
https://reachmd.com/programs/cme/Cases-From-the-Real-World-61-Year-Old-With-Wet-AMD-With-a-High-Treatment-Burden/33169/Join Drs. Ted Leng and Danny Mammo as they explore their real-world experience with second-generation retinal agents for nAMD.